MPS Pharmaa equity nearly wiped out as core business remains stalled
The company reported a net loss of ₹1.02 crore for FY26, leaving it with just ₹6.85 lacs in equity as auditors flag missing investment certificates.
— 1 earlier story on MPS Pharmaa Ltd. →What's new
- Standalone net loss of ₹1.02 crore for FY26 with zero revenue from core operations.
- Auditors issued a qualified opinion over missing investment certificates worth ₹53.80 lacs.
- Stalled capital projects valued at ₹2.41 crores lack required impairment testing.
Why this matters
The company is effectively a shell with no operational income and a balance sheet that has nearly collapsed. With equity down from ₹1.08 crores to just ₹6.85 lacs, the firm faces acute insolvency risk.
What we're watching
- Whether the company can address the auditor's qualification on missing investment certificates.
- Any signs of a potential revival or formal liquidation process.
- The company's ability to continue as a going concern given its current financial state.
The full read
MPS Pharmaa is in a state of financial collapse. For the fiscal year ending March 31, 2026, the company recorded a net loss of ₹1.02 crore while generating zero revenue from its core business. Total income for the period was a mere ₹3.56 lacs, down from ₹4.77 lacs in the prior year. The balance sheet is now severely impaired, with accumulated losses of ₹19.04 crores leaving the company with only ₹6.85 lacs in total equity, a sharp drop from ₹1.08 crores a year ago. Statutory auditors have issued a qualified opinion, citing an inability to verify physical certificates for investments worth ₹53.80 lacs and a failure to conduct impairment testing on stalled capital projects valued at ₹2.41 crores. Given the company's ₹3 crore market capitalization, these results raise immediate questions about its viability as a going concern.
Questions answered
- How much revenue did the company generate during the fiscal year?
- The company generated no revenue from its core business. It reported a total income of only ₹3.56 lacs, all of which came from non-operational sources.
- What specific concerns did the statutory auditors raise?
- Auditors issued a qualified opinion because the company could not produce physical certificates for investments worth ₹53.80 lacs. They also flagged the lack of impairment testing for stalled capital projects valued at ₹2.41 crores.
- How has the company's equity position changed over the last year?
- Equity has eroded from ₹1.08 crores in the previous year to just ₹6.85 lacs as of March 31, 2026. This decline follows accumulated losses reaching ₹19.04 crores.
- What is the current scale of the company?
- MPS Pharmaa is a nano-cap entity with a market capitalization of approximately ₹3 crores.
Story so far
All notes on ADVIKLA →- 28 May 2026 · 2:38 PM IST MPS Pharmaa equity nearly wiped out as core business remains stalled
- today MPS Pharmaa reports net loss of ₹1.02 cr as operations remain stalled